Somewhere between the pharmacy and the injection there is sometimes a second bottle. It contains water, it costs almost nothing, and it is an FDA-approved drug product with its own label, its own indication and its own contraindication — none of which most people ever read, because it arrives looking like packaging rather than medicine. If your compounded GLP-1 came as a powder with instructions to mix it, that bottle is doing more work than the plastic it is made of suggests. What the peptide vial itself holds is a separate question; this is about the liquid you are told to add to it.
What a diluent is, and the two kinds of water
Reconstitution means dissolving a dried solid into a liquid. Dilution means thinning a solution that already exists. Both need a vehicle, and for injectable peptides that vehicle is almost always one of two water products that look identical and are not interchangeable.
Sterile Water for Injection carries no preservative. It is intended to be used once and discarded, and because it contains no solute it is hypotonic; the bacteriostatic label warns that intravenous administration of water without a solute can cause hemolysis, and that the preparation must be made approximately isotonic before use.[1] That is not a caution about the peptide. It is a caution about water.
Bacteriostatic Water for Injection, USP is the preserved version. Its label describes a sterile, nonpyrogenic preparation of water for injection containing 0.9% — 9 mg/mL — or 1.1% — 11 mg/mL — of benzyl alcohol added as a bacteriostatic preservative, supplied in a multiple-dose container from which repeated withdrawals may be made, at a pH of 5.7 with a range of 4.5 to 7.0.[1] The preservative is the entire difference, and it is what allows the same bottle to be entered more than once — the same logic that governs multi-dose presentations of the approved products, which the vial-versus-pen article sets out.
One more thing both labels agree on: this is a diluent and nothing else. The indication reads that the preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.[1] Hold onto that last clause.
Benzyl alcohol and the neonatal contraindication
The bacteriostatic bottle carries a warning in capitals on the vial face: not for use in neonates.[1] It is one of the few contraindications in the pharmacopeia that traces to a single identified episode. In 1982 the New England Journal of Medicine published the report that connected benzyl alcohol poisoning to what became known as the gasping syndrome in premature infants.[2] The label language that followed is still there: benzyl alcohol has been associated with toxicity in neonates, data are unavailable on other preservatives in that age group, and where water is required for preparing or diluting medications for neonates, only preservative-free Sterile Water for Injection should be used.[1]
The label also puts numbers on the exposure, and they are worth reading because they explain why this is a neonatal rule rather than a general one. Experimental studies in several animal species indicated that an estimated intravenous dose of up to 30 mL of 0.9% benzyl alcohol may be given to an adult without toxic effects, while an estimated 9 mL administered to a 6 kg infant or neonate is potentially capable of producing blood pressure changes.[1] Animal work supports the same reading of the mechanism: in mice the acute toxicity of benzyl alcohol — sedation, dyspnea, loss of motor function — was attributable to the alcohol itself rather than to its metabolite benzaldehyde, and blocking alcohol dehydrogenase made it markedly worse.[3]
For an adult drawing a fraction of a milliliter at a time, the quantities involved are small. The contraindication is real, it is narrow, and it matters most for anyone who is pregnant, might become pregnant, or is handling these products around an infant. It also matters to anyone sensitized to benzyl alcohol as a contact allergen, which is a different failure mode with a different literature behind it.
The sentence on the label that contradicts the instruction sheet
Now the clause held onto earlier. Under PRECAUTIONS, the bacteriostatic water label says: when diluting or dissolving drugs, mix thoroughly and use promptly; do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.[1]
Read that against the reason people buy bacteriostatic water in the first place. The preservative is understood, in the informal explanations that circulate, as the thing that lets a mixed vial sit in a fridge for weeks. The label does not say that. It says mix and use promptly, and it makes any storage at all conditional on direction from the manufacturer of the solute — the company that made the drug being dissolved. The preservative protects the water from what you introduce when you puncture it. It says nothing about whether the drug in the mixture is still intact.
For an approved product that direction exists: the manufacturer performed the studies and printed an in-use time. For a compounded preparation there is no approved labeling, so the only direction is whatever the compounder or the telehealth platform wrote. FDA’s guidance for outsourcing facilities sets the fallback where supporting data has not been generated — an in-use time of less than 4 hours at room temperature or less than 24 hours refrigerated.[4] Hours. Where the date on the unmixed vial comes from is the beyond-use dating article’s subject, and the same rule applies to the mixture: storage plus use must fit inside the assigned date, not extend past it.
What the preservative does to the protein
There is a second reason the label says use promptly, and it belongs to physical chemistry rather than microbiology. Antimicrobial preservatives can make proteins aggregate.
The most directly relevant study did exactly what a patient reconstituting a peptide does. Researchers took a lyophilized therapeutic protein, recombinant human interleukin-1 receptor antagonist, and reconstituted it with 0.9% w/v benzyl alcohol in water — bacteriostatic water, by another name. Reconstitution with the preservative produced a greater degree of aggregation than reconstitution with plain water, and the extent of it tracked how much native secondary structure the protein had retained through freeze-drying.[5] The authors’ own conclusion was that a multidose lyophilized formulation intended for benzyl alcohol reconstitution has to be engineered for it, with a stabilizing excipient and the right protein concentration and tonicity.
A second study ranked the common preservatives against each other and found the ordering held regardless of which protein was used: m-cresol first, then phenol, then benzyl alcohol, then phenoxyethanol.[6] That is a genuinely two-sided result. Benzyl alcohol is not inert, but of the preservatives in routine injectable use it is the gentler end of the range — gentler than the phenol carried by several approved multi-dose presentations.
The honest limit on all of this: neither study used semaglutide or tirzepatide, and no published work on benzyl alcohol with either molecule was retrievable for this article. What the literature establishes is a mechanism and a direction, not a magnitude for these drugs. It matters because aggregates are one of the recognized drivers of unwanted immune responses to protein and peptide products, which is where the antibody article takes the thread.
A pharmacy mixing it and you mixing it are not the same act
When a compounding pharmacy reconstitutes, the manipulation happens inside a controlled air environment, under a written and validated procedure, by someone whose aseptic technique is periodically tested, with the resulting preparation subject to release testing and given an assigned date. Every one of those is an input to the number on the label.
When a patient reconstitutes at a kitchen counter, none of them applies. The mixture is new, its antimicrobial effectiveness has not been demonstrated at that final concentration, the aseptic technique is unvalidated, and the in-use time attached to it is whatever an instruction card asserts. That is not an argument that home preparation is reckless — the entire self-injection category rests on people doing careful things at home, and technique is teachable, which is its own subject. It is an argument that the two situations should not be described with the same sentence, and that a product sold ready to inject removes a whole class of variables that a mix-it-yourself product hands to the buyer.
So the questions worth asking are short. Does the product arrive ready to inject, or do I have to mix it? If I mix it, which diluent, how much, and what is the in-use time of the result — in hours or days, with a starting point named? Is that in-use time supported by anything, or is it an assertion? And is the diluent an approved Bacteriostatic or Sterile Water for Injection product from a named manufacturer, or something unlabeled that arrived in the same box? A supplier that can answer all four in writing has thought about the problem. A supplier that treats the water as packaging has told you where its attention is.